MOMałgorzata OlęDzka

Małgorzata OlęDzka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Małgorzata OlęDzka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A multidisciplinary approach to the patient with systemic lupus erythematosus: a narrative review

    by Barbara OlęDzka, Michał Piątkiewicz, Małgorzata OlęDzka, Wiktoria Mazepa, Sara Zahra Omidi, Kaja Pruszkowska, Zofia Rogowska, Elżbieta Kowalska-OlęDzka

    Background: Lupus erythematosus is a chronic multisystem autoimmune disease affecting both internal organs and the skin. It may present as a skin-limited condition, referred to as cutaneous lupus erythematosus, or as a potentially life-threatening systemic disorder, systemic lupus erythematosus. Skin involvement is observed in up to 80% of patients with systemic lupus erythematosus, and cutaneous disease represents the initial manifestation of the systemic form in approximately 25% of cases. Despite this substantial burden, knowledge of the disease among physicians and nurses remains inconsistent, and hospitalization affects roughly 10% of patients annually, underscoring the need for a consolidated, multidisciplinary summary of current management.Aim of the study: The aim of this study was to synthesize current clinical knowledge regarding lupus erythematosus, outline diagnostic and therapeutic strategies, and emphasize the critical role of multidisciplinary care, patient education, and addressing the psychological burden associated with the disease.Materials and methods: A narrative review was conducted through a comprehensive literature search across PubMed, Scopus, and Web of Science (between 17 February and 29 March 2026). A total of 50 publications were included, comprising clinical practice guidelines, systematic reviews and meta-analyses, randomized controlled trials, and original clinical studies, including the EULAR/ACR criteria.Results: Lupus diagnosis relies primarily on the 2019 EULAR/ACR criteria. The cornerstone of treatment comprises antimalarial drugs, supported by immunosuppression and biological therapies. Non-pharmacological management remains crucial, particularly strict photoprotection and complete smoking cessation. The multisystem nature of the disease requires care coordinated by a rheumatologist in close collaboration with a cardiologist, nephrologist, dermatologist, and other specialists. The patients' psychological burden, including depression, necessitates psychiatric support and modern educational tools, which directly improve treatment adherence, a pressing concern, as non-adherence affects up to 62% of patients with SLE, with depression and polypharmacy independently increasing the risk.Conclusions: Effective management of lupus extends beyond pharmacology alone. Clinical success requires close cooperation within a multidisciplinary team, integrated psychological support, and ongoing patient education, which collectively help prevent relapses and enhance overall quality of life.

  • Open Access

    TARGETING TYPE I INTERFERON SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL AND SAFETY PERSPECTIVES ON ANIFROLUMAB THERAPY

    by Sara Zahra Omidi, Daria Valipur Kolti, Jerzy Klimas, Barbara Anna OlęDzka, Wiktoria Mazepa, Małgorzata OlęDzka, Michał Piątkiewicz, Kaja Pruszkowska, Zofia Rogowska

    Anifrolumab is a fully human IgG1 monoclonal antibody targeting the IFNAR1 subunit of the type I interferon receptor. By inhibiting the JAK-STAT signaling pathway and suppressing interferon-stimulated gene expression, anifrolumab represents a targeted therapy based on disease pathophysiology. The drug has been approved as an add-on treatment for adult patients with moderate to severe systemic lupus erythematosus particularly in patients in whom standard therapies such as systemic glucocorticoids and hydroxychloroquine have failed to achieve the desired outcomes. The efficacy of anifrolumab has been assessed in several randomized clinical trials, which demonstrated a significant reduction in disease activity, decreased rates of disease flares, and improvement in cutaneous and musculoskeletal manifestations. Another clinically relevant outcome was the possibility to reduce glucocorticosteroid doses. Further analyses also suggest a beneficial effect of anifrolumab in lupus nephritis and indicate its superiority over standard therapy. Anifrolumab has demonstrated a favorable safety profile, with no significant increase in the risk of serious adverse events or opportunistic infections. The most frequently reported adverse events were upper respiratory tract infections as well as varicella and herpes zoster infections. In Poland, anifrolumab is registered exclusively for the treatment of adults with moderate to severe systemic lupus erythematosus as an adjunct to standard therapy. However, evidence from clinical trials and case series suggest the potential for broader application of this drug in dermatology in the coming years. In the future, anifrolumab may also be considered a therapeutic option in refractory cases of cutaneous lupus erythematosus.